2012 년 9 월 월례집담회 증례문제 풀이 2012.09.06 여의도성모병원 진단검사의학과 임상강사 한상봉.

Slides:



Advertisements
Similar presentations
IGRAs for Diagnosis of Tuberculosis:
Advertisements

VDH TB Control and Prevention Program
TB: The Coventry perspective
QuantiFERON®-TB Gold Test
CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):
3 Self-Study Modules on Tuberculosis Targeted Testing and
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Latent TB When infected with M Tuberculosis, but do not have active tuberculosis disease. Patients are not infectious. TB infections in Australia are predominantly.
TB Presentation for Healthcare Students
Group B3 (BCG replacement strategy) Define the immunogenicity endpoints to be used for the preclinical studies and the clinical trial Claude MERIC, Narges.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG.
The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of the TB Skin Test Over? Theodore F. Them, MD, MS, PhD, MPH, FACOEM.
Interferon-gamma Release Assays: the Good, the Bad, and the Ugly Susan E. Dorman, MD Center for TB Research Johns Hopkins University School of Medicine.
TB in Nebraska, New Challenges & Solutions. Mycobacterium.
New Tools for Diagnosing Latent TB
OnSite TB/HIV Ab Rapid Test 2 in 1 test kit
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Learning Objectives How to detect HIV antibodies/HIV infection?
HIV Testing CDC power point edited by M. Myers
Update on Interferon Gamma Release Assays for the Laboratory Detection of Mycobacterium tuberculosis Infection David Warshauer, Ph.D., D(ABMM) Deputy Director.
October 3, Serial Testing of Health Care Workers for Tuberculosis Using Interferon-γ Assay Madhukar Pai, et. al. American Journal of Respiratory.
Interferon Gamma Release Assays (IGRAs) for the Diagnosis of TB: Can We Replace the TST? Helene M. Calvet, MD Health Officer and TB Controller Long Beach.
Screening for Tuberculosis Infection
Allen Kraut, MD, FRCPC Medical Director, Occupational Health WRHA
Sample & Assay Technologies For Internal Use Only Effectively screening for Latent TB HIV/STD/TB/Hepatitis Symposium North Dakota April Mary.
Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.
Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study M Busch, representing REDS-II Parvo.
Director of Scientific Affairs
HIV and TB Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health Program in Global Health, Division of Infectious Diseases David Geffen.
Tuberculosis Research of INA-RESPOND on Drug-resistant
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES XVIII International AIDS Conference, July , Vienna Austria Recent Trends in estimated HIV-1.
PatientAge INF-  on blood Culture 1 st evaluation 2 nd evaluation Days for positivization Identification DA1y 2mPOS13 daysM. tuberculosis EOA4y 3mIND.
Phthisiology Diagnosis of TB. Diagnosis of TB-disease. Clinical signs. Investigations. Lecture 2.
Adult Medical-Surgical Nursing Respiratory Module: Tuberculosis.
Traditional and Novel Diagnostic Tests of TB Infection Toru Mori, MD, PhD Research Institute of Tuberculosis/JATA National Institute of Infectious Diseases,
Screening for TB.
STATENS SERUM INSTITUT An estimated 15 million active cases, leading to….. An estimated 9 million new infections Approx 2 million deaths Approx 2 Billion.
IGRAs: Should they replace the TST in the identification of latent tuberculosis? Objectives Describe how interferon-gamma release assays (IGRAs) work.
The Enzyme Linked Immunosorbent Assay (ELISA).. Capture ELISAs Antigen Capture: In this, more specific approach, a capturing Ab is adsorbed onto the solid.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Tuberculosis Case Study Presenter Xoliswa Poswa TB Laboratory, NHLS/CMID.
3 Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and.
Update in the Diagnosis of Tuberculosis in Children Ana M. Alvarez, MD, FPIDS Associate Professor Division of Pediatric Infectious Diseases and Immunology.
Contact Investigation Dr. Essam Elmoghazy. Contact Investigations – A Crucial Prevention Strategy On average, 10 contacts are identified for each person.
GERIATRIC TUBERCULOSIS: ISSUES Dr. (Prof.)Vijay Kumar Arora Vice Chancellor Ex Director NITRD Delhi,Ex Director-professor JIPMER, Ex Additional DGHS GOI.
Mantoux – in vivo detection of specific cell immunity after exposition to antigen - burden of patient by antigen - possible immunodeficiency of patients.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
3.What is the principle behind the Quantiferon-Tb assay for TB?
Laboratory Diagnosis of Tuberculosis By Dr. Faten Aly Shoukry, Ph D Consultant & Head of Microbiology Department, Abbassia Chest Hospital.
Mycobacteria İ. Çağatay Acuner M.D., Clinical Microbiologist, Associate Professor Department of Microbiology Faculty of Medicine, Yeditepe University,
Comparison of a New ESAT-6/ CFP-10 Peptide-Based Gamma Interferon Assay to Tuberculin Skin Test for Tuberculosis Screening in a Moderate Risk Population.
LATENT TB IN ADULTS by Assoc. Prof. Pang Yong Kek 1.
Diagnosis of pulmonary tuberculosis
What’s New With Your Maryland State Lab. Richard Oatis Supervisor, Mycobacteriology State of Maryland Department of Health and Mental Hygiene Labs Administration.
IFN-γ Release Assays in the Diagnosis of Latent Tuberculosis Infection among Immunocompromised Adults Gil Redelman-Sidi and Kent A. Sepkowitz Am J Respir.
Western blotting Pete Jones.
Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.
Shingai Machingaidze, Suzanne Verver, Humphrey Mulenga, Deborah-Ann Abrahams, Mark Hatherill, Willem Hanekom, Gregory D. Hussey, and Hassan Mahomed Am.
TB: The Elispot In The Room Dr Jessica Potter TB Research Registrar Barts Health NHS Trust.
GENE EXPRESSION STUDY ON PROTEIN LEVEL
Tuberculosis Screening
Assay Parameters Affecting Variability Of QuantiFERON®-TB Gold In-Tube Assay Results Whitworth WC1, Mazurek GH1, Goodwin DJ2 1Centers for Disease Control.
Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice John Z. Metcalfe, Adithya Cattamanchi1, Charles E. McCulloch, Justin D.
Volume 73, Issue 6, Pages (December 2016)
QuantiFERON® Blood Test for the Detection of
CDC Guidelines for Use of QuantiFERON®-TB Gold Test
Feasibility of commercial interferon-γ-based methods for the diagnosis of latent Mycobacterium tuberculosis infection in Finland, a country of low incidence.
Presentation transcript:

2012 년 9 월 월례집담회 증례문제 풀이 여의도성모병원 진단검사의학과 임상강사 한상봉

증례 –F/51 –C.C : 건강검진상 발견된 고혈압과 단백뇨 (Dip stick 4+), 신기능이상 (Cr.: 1.5 mg/dL) 으로 입원 ( ) –4.21 Kidney Bx. : Congo red stain(+): apple-green birefringence  primary amyloidosis –4.26 serum & 24hr urine protein EP : M spike(+), serum & urine IFE : IgG, lambda type 의 monoclonal band –4.29 BM Bx. : Normocellular Marrow with Slightly Increased Plasma Cells (2.6%)

– 결핵균 특이항원 인터페론 - 감마 검사 (Quantiferon ® -TB Gold) 결핵감염 임상증상 (-), Chest X-ray : WNL  sputum AFB & culture, TB PCR 검사 시행 (X) – 치료 : Thalidomide/Dexamethasone 항암요법을 2 cycle 시행 – 결핵균 특이항원 인터페론 - 감마 검사에 대한 추적 검사 검사일자 NilTB AgMitogenTB Ag-NilMitogen-Nil 2011/5/ 약품명용량 및 용법투여기간 Thalidomide100mg po qd5/11 ~ 5/25, 6/8 ~ 6/13 Dexamethasone40mg IV5/12 ~ 5/14, 6/9 ~ 6/12 Aspirin100mg po qd 5/1 ~ 6/13 ( 계속 복용 ) Valsartan80mg po qd 5/1 ~ 6/13 ( 계속 복용 ) Atorvastatin10mg po qd 5/1 ~ 6/13 ( 계속 복용 ) Lansoprazole15mg po qd5/1 ~ 6/13 ( 계속 복용 ) 검사일자 NilTB AgMitogenTB Ag-NilMitogen-Nil 2011/6/

문제 1. 2 회에 걸쳐 시행된 이 환자의 Quantiferon ® -TB Gold 검사결과 를 해석하고 결과를 판정 (Negative/Indeterminate/Positive) 하시오. 만약 2 회의 검사결과에 차이가 있다면 그 원인은 무엇이겠는가 ? 문제 2. Quantiferon-TB Gold 를 포함한 interferon-gamma release assays (IGRAs) 에 영향을 미칠 수 있는 요인에 대해 고찰하시오.

Quantiferon ® -TB Gold In-Tube (QFT-GIT) –Principle Cell Mediated Immune (CMI) response test Latent or active TB infection 시 → Effector T-lymphocyte 가 MTB highly specific peptide Ag. 을 비롯한 여러 mycobacterial Ag. 에 감작됨 → QFT-GIT test : 감작된 Effector T-lymphocyte 를 MTB highly specific Ag. 으로 stimulation 시켜 IFN- Ƴ를 분비를 유도. → IFN- Ƴ를 검출

–MTB 의 highly specific peptide Ag. 종류 ① Early Secretory Antigenic Target-6 (ESAT-6) ② Culture Filtrate Protein-10 (CFP-10) ③ TB7.7 특징 –BCG vaccination 에 영향을 받지 않는다. –M. kansasii, M. szulgai, M. marinum 을 제외한 non tuberculosis mycobacteria 에 영향을 받지 않는다. –Induce IFN- Ƴ responses

–Procedure »Three collection tubes Nil tube : negative control 구성 : saline IFN- Ƴ, heterophile antibody effects, non specific IFN- Ƴ의 background level 을 측정 TB Antigen tube : test tube MTB highly specific peptide Ag. (ESAT-6, CFP-10, TB7.7) 가 포함 Mitogen tube : positive control Phytohemagglutinin : non-specific stimulator of T-cells. individual’s immune status 확인

Nil TB Antigen minus NilMitogen QFT [IU/mL] [IU/mL] minus Nil Result Report / Interpretation [IU/mL] ≤ 8.0 ≥ 0.35 and ≥ 25% of Nil valueAnyPositive 1 M. tuberculosis infection likely < 0.35 OR ≥ 0.35 and < 25% of Nil value ≥ 0.5Negative M. tuberculosis infection NOT likely < 0.5 Indeterminate Results are indeterminate for TB Antigen responsiveness > 8.0Any Guidelines for interpreting test result (recommended by CDC) 1 Where M. tuberculosis infection is not suspected, initially positive results can be confirmed by retesting the original plasma samples in duplicate in the QFT ELISA. if repeat testing of one or both replicates is positive, the test result is considered positive.

검사일자 NilTB AgMitogenTB Ag-NilMitogen-Nil 2011/5/ 검사일자 NilTB AgMitogenTB Ag-NilMitogen-Nil 2011/6/ Nil : 0.20 <8.0 TB Ag-Nil : 0.60 >0.35 and >0.05(25% of Nil)  Positive Nil : TB Ag-Nil : 0.04 <0.35  Negative

–Cut-off(0.35IU/mL) 주위 값의 변화 (cellestis FAQ) 검사 자체의 variability(<15% CV) 가 존재하기 때문에 infection status 가 변하지 않은 것으로 판단 Guidelines for interpreting test result : Where M. tuberculosis infection is not suspected, initially positive results can be confirmed by retesting the original plasma samples in duplicate in the QFT ELISA. 검사일자 NilTB AgMitogenTB Ag-NilMitogen-Nil 2011/5/

northern California households 의 63 명을 대상으로 3 개월 간격으로 두 번 방문 측정 결과 –QFT-GIT (+)  (-) : 5/15 (33%) –QFT-GIT (-)  (+) : 3/48 (6.3%) 8/63 (13%)

The Stanford Hospital and Clinics 에서 2011 년 11 월 10~20 일 사이의 QFT-GIT 양성률이 기존 평균인 10% 에서 31% 로 일시적 증가를 보임 (P<0.001, chi-squared test)

처음에 false-positive 결 과를 보인 81 명에 대해서 새 lot. 의 TB Ag tube 로 재검한 결과 91% 가 negative.  최근 tube 및 시약의 lot 변경여부 확인 및 최근 양성률 확인 필요

Cellestia FAQ –What is the attitude to a QFT positive response without information about a recent contact? Additionally, infections by other mycobacteria (eg. M. kansasii) can also potentially lead to positive results. –Incubation time 이 24h 을 넘어갈 경우, central memory T-cell 의 effector T-cell 로의 분화에 의해서 old/cured TB infection 이 있었던 환자에서 false-positive 가능

Quantiferon-TB Gold 를 포함한 interferon-gamma release assays (IGRAs) 에 영향을 미칠 수 있는 요인 –Indeterminate Low response to Mitogen (Mitogen-Nil<0.5 IU/mL) –Insufficient lymphocytes –reduced lymphocyte activity due to improper specimen handling, incorrect filling/mixing of the Mitogen tube –HIV infection, AIDS or immune suppressive treatment –may be transient  retesting the individual after a period of a few weeks

 High response to Nil (>8.0 IU/ml) -Longer than 16 hours from blood draw to incubation at 37 ℃ -Incomplete washing of the ELISA plate -Excessive levels of circulating IFN- Ƴ or presence of heterophile antibodies

PLoS One. 2011;6(8):e Epub 2011 Aug 19. Analysis of factors lowering sensitivity of interferon-γ release assay for tuberculosis. Hang NT, Lien LT, Kobayashi N, Shimbo T, Sakurada S, Thuong PH, Hong le T, Tam do B, Hijikata M, Matsushita I, Hung NV, Higuchi K, Harada N, Keicho N. NCGM-BMH Medical Collaboration Center, Hanoi, Viet Nam. PositiveNegativeIndeterminateP*P* n% (95% CI)n n All (n=504) (89.6–94.4)244.8 (3.1–7.0)153.0 (1.7–4.9) HIV positive (n=44) (45.5–75.6)511.4 (3.8–24.6) (15.0–42.8)<0.001 HIV negative (n=459) (92.8–97.0)194.1 (2.5–6.4)30.7 (0.1–1.9)

Allele nameNumber of alleles (% [95%CI])P*P* TotalIGRA positiveIGRA-negative 2n ‡ =1008 ‡2n=9302n=48 HLA-DRB (33.4 [30.5–36.4])318 (34.2 [31.1–37.3])11 (22.9 [12.0–37.3]) (12.8 [10.8–15.0])119 (12.8 [10.7–15.1])6 (12.5 [4.7–25.2])> (6.1 [4.7–7.7])44 (4.7 [3.5–6.3])11 (22.9 [12.0–37.3])< (5.9 [4.5–7.5])53 (5.7 [4.3–7.4])5 (10.4 [3.5–22.7]) (5.4 [4.0–6.9])49 (5.3 [3.9–6.9])4 (8.3 [2.3–20.0]) (5.3 [4.0–6.8])51 (5.5 [4.1–7.1])0 (0.0 [0.0–7.4]) (5.1 [3.8–6.6])49 (5.3 [3.9–6.9])2 (4.2 [0.5–14.3])>0.999 others264 (26.2 [23.5–29.0])247 (26.6 [23.7–29.5])9 (18.8 [8.9–32.6])0.312 HLA-DQB (38.0 [35.0–41.1])361 (38.8 [35.7–42.0])12 (25.0 [13.6–39.6]) (15.1 [12.9–17.4])138 (14.8 [12.6–17.3])9 (18.8 [8.9–32.6]) (9.3 [7.6–11.3])87 (9.4 [7.6–11.4])6 (12.5 [4.7–25.2]) (9.1 [7.4–11.1])74 (8.0 [6.3–9.9])12 (25.0 [13.6–39.6]) (8.0 [6.4–9.9])76 (8.2 [6.5–10.1])3 (6.3 [1.3–17.2])> (6.9 [5.5–8.7])68 (7.3 [5.7–9.2])0 (0.0 [0.0–7.4]) (4.2 [3.0–5.6])40 (4.3 [3.1–5.8])1 (2.1 [0.1–11.1])0.717 others94 (9.3 [7.6–11.3])86 (9.2 [7.5–11.3])5 (10.4 [3.5–22.7])0.797

Compared with the patients who had test-positive results, those with negative results were significantly –older (median age: 48.9 [IQR, 33.2–62.6] vs 39.0 [IQR, 29.1– 50.6], P=0.036) –lower BMI (median BMI: 16.6 [IQR, 13.9–17.9] vs 18.3 [16.9– 19.7] kg/m 2, P=0.0001)

경청해 주셔서 감사합니다